2018

Partners in Excellence
Executive Summary for Retail Pharmacy
Purpose
The Partners in Excellence Program forms the basis for HealthPartners’ financial and public recognition for pharmacies achieving high levels of performance in clinical quality, patient experience, and affordability targets. HealthPartners Pharmacy Administration is focused on affordability, improving health, reducing costs, increasing accessibility and providing a great member experience.

Goals
- Promote safe, effective, timely, patient centered, equitable and efficient care.
- Provide financial and public recognition to pharmacies for excellent performance, designated as gold and silver recognitions.
- Reinforce:
  - Prevention
  - Evidence based care
  - Efficient care
  - Population based care
  - Continuous improvement

Principles
- Payment methodologies will be easily communicated and understood.
- Measurement system will be valid and reliable.
- Reward so that there is true motivation for, and recognition of, improved performance.
- Program will continuously evolve.

Data Communication
- Comparative performance results will be provided to each pharmacy group annually.
- Final results will be available following the end of year in review.

Program Eligibility
- Pharmacies must dispense at least 6,500 prescriptions for HealthPartners members in Minnesota and Iowa in 2018 to be eligible for program inclusion.

Inclusion for Applicable Measures
- Pharmacy groups will not be eligible for any measure(s) for which that pharmacy has fewer than 30 eligible members.
## HealthPartners Pharmacy Partners in Excellence Targets, 2018

Gold will pay 100% of bonus pool percentage for each target.  
Silver will pay 25% of bonus pool percentage for each target.

<table>
<thead>
<tr>
<th>2018 Criteria</th>
<th>Gold Target</th>
<th>Silver Target</th>
<th>% of Bonus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressant Medication Management – Continuation Phase</td>
<td>72%</td>
<td>67%</td>
<td>25%</td>
</tr>
<tr>
<td>Asthma Medication Adherence</td>
<td>70%</td>
<td>60%</td>
<td>25%</td>
</tr>
<tr>
<td>Diabetes Medication Adherence</td>
<td>92%</td>
<td>88%</td>
<td>25%</td>
</tr>
<tr>
<td>Cholesterol-Continuous Persistency</td>
<td>72%</td>
<td>62%</td>
<td>25%</td>
</tr>
</tbody>
</table>

### Criteria Description

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
<th>Who (denominator)</th>
<th>What (numerator)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication Management – Continuation (Antidepressant)</td>
<td>The percentage of members 18 years of age and older who were treated with antidepressant medication and had a diagnosis of major depression during the measurement period for dates of January 1, 2018 - December 31, 2018.</td>
<td>Members 18 years of age and older who remained on an antidepressant medication treatment for at least 180 days (6 months).</td>
<td>Members who remained on an antidepressant medication treatment for at least 180 days (6 months) following their first prescription for an antidepressant.</td>
</tr>
<tr>
<td>Medication Adherence (Asthma)</td>
<td>The percentage of members meeting a 75% proportion of days covered (PDC) for controller medications.</td>
<td>Members with a diagnosis of asthma and 2 or more prescriptions of a controller medication in the measurement period of January 1, 2018 - December 31, 2018.</td>
<td>Members meeting a 75% proportion of days covered (PDC) of controller medications during the measurement period of Jan – Dec 2018 as measured by days’ supply: days in period.</td>
</tr>
<tr>
<td>Medication Adherence (Diabetes)</td>
<td>The percentage of members meeting an 80% proportion of days covered (PDC) for oral hypoglycemic medications.</td>
<td>Members with a diagnosis of diabetes filling 2 or more prescriptions of an oral hypoglycemic medication in the measurement period of January 1, 2018 - December 31, 2018.</td>
<td>Members meeting an 80% proportion of days (PDC) of oral hypoglycemic during the measurement period as measured by days’ supply: days in period.</td>
</tr>
<tr>
<td>Continuous Persistency (Cholesterol)</td>
<td>The percentage of members starting cholesterol medications and remained on those medications for 180 days.</td>
<td>Members with a new prescription for a statin medication in the measurement period of January 1, 2018 - December 31, 2018.</td>
<td>Members with at least 180 days of prescriptions filled for statin medication.</td>
</tr>
</tbody>
</table>